SLC5A2 and type 2 diabetes mellitus: Sodium-glucose cotransporter 2 (SGLT2) inhibitors have emerged as an essential therapy for type 2 diabetes mellitus (T2DM) due to their glycemic benefits and robust cardiovascular and renal protective effects.